The DEA's marijuana rescheduling hearing, set for June 29, has drawn intense attention from cannabis operators, investors, and compliance professionals watching for signs of what a Schedule III designation might mean for their businesses. But one company argues the hearing itself is almost beside the point. MMJ International Holdings has filed a legal challenge in the United States Court of Appeals for the D.C. Circuit that targets not what the DEA decides - but whether the agency had the legal authority to decide it in the first place.
That distinction matters enormously for anyone operating a licensed cannabis business. Dispensary owners tracking rescheduling for its potential 280E tax relief, multi-state operators modeling wholesale pricing under a revised federal framework, and technology vendors like indicaonline.com serving licensed retailers in state-regulated markets all have a stake in whether the federal regulatory structure underpinning those markets survives judicial review intact. A court ruling that voids or narrows the DEA's Final Order could leave the industry in a more uncertain position than it occupied before the rescheduling process began.
In Case No. 26-1136, petitioners filed their Statement of Issues on June 18, identifying thirteen separate legal grounds for review of DEA's April 2026 Final Order. The list is not a standard administrative grievance. It raises questions about statutory authority under the Controlled Substances Act, treaty obligations under the Single Convention on Narcotic Drugs, the Major Questions Doctrine, equal-protection concerns, and - most pointed of all - whether the administrative structure used to produce the Final Order is constitutionally defective under Article II.
The Constitutional Problem That Testimony Cannot Fix
The Article II argument draws directly from the Department of Justice's own concession in MMJ BioPharma Cultivation Inc. v. Bondi, in which DOJ acknowledged that multiple layers of removal protections applicable to Administrative Law Judges raise separation-of-powers concerns. MMJ International Holdings has made that concession central to its challenge. The argument is straightforward: if the adjudicative structure itself violates the Constitution, the proceedings it produces are legally suspect regardless of what the administrative record contains.
"You can hold a hearing, but you can't out-hear a constitutional problem," said Duane Boise, CEO of MMJ International Holdings. That framing captures what makes this challenge different from typical administrative disputes about evidence weight or regulatory interpretation. Questions of statutory authority, constitutional structure, and treaty compliance are not resolved by witness testimony. They are resolved by federal judges applying legal standards - and those questions are already before the D.C. Circuit.
Here's the catch for the broader industry: the June 29 hearing will build an administrative record that could take months or years to work through the system, while the court proceeding runs in parallel. Whatever emerges from the hearing room, the D.C. Circuit's ruling will shape what any rescheduling order actually means in practice.
A Novel Regulatory Scheme and Who It Benefits
Among the thirteen issues identified in the filing, one deserves particular attention from operators and compliance professionals. Petitioners argue that DEA's Final Order created a hybrid regulatory scheme - placing certain marijuana products in Schedule III while retaining enforcement features historically associated with Schedule I and II substances. They further argue that the order treats chemically identical products differently based on licensing status rather than chemical composition.
That distinction is not abstract. Under the current framework, a pharmaceutical cannabinoid developed through FDA-regulated chemistry, manufacturing, stability, and clinical-development pathways would be treated differently from a commercially produced cannabis product sold through a state-licensed dispensary - even if both products contain the same active compound. Whether Congress authorized that kind of distinction is a question the D.C. Circuit will have to answer. If the court finds it did not, the legal basis for the entire tiered system could be in question.
For dispensary operators, that risk is operational. A rescheduling order that survives administrative review but fails on judicial review doesn't deliver the 280E relief operators have anticipated. It doesn't change the compliance structure under which licensed retailers manage inventory, labeling, and point-of-sale reporting. And it doesn't resolve the banking access problems that have defined cannabis retail since the beginning.
What Licensed Operators Should Actually Be Watching
The practical takeaway for cannabis businesses is not that the June 29 hearing is irrelevant - it isn't. The administrative record it produces will matter if and when the D.C. Circuit evaluates the DEA's reasoning. But the hearing alone will not determine whether rescheduling stands.
The questions now before the court - statutory authority, administrative structure, treaty compliance, equal protection - will be decided on legal grounds that the hearing cannot resolve. That means the timeline for any business certainty around federal rescheduling is longer than the June 29 date suggests. Operators who have made financial plans contingent on near-term 280E relief, or who have restructured compliance programs in anticipation of a Schedule III framework, should understand that both outcomes remain legally unsettled.
The administrative process created the record. The court will decide the law. Those are two different things - and right now, only one of them is fully in play.
